Unique ID issued by UMIN | UMIN000002389 |
---|---|
Receipt number | R000002935 |
Scientific Title | Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma |
Date of disclosure of the study information | 2009/08/26 |
Last modified on | 2023/02/28 22:24:39 |
Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma
Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma
Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma
Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma
Japan |
Bronchial asthma
Pneumology |
Others
NO
To examine clinical effects of omalizumab in bronchial asthma patients by using impulse oscillometry, chest computed tomography, methacholine airway responsiveness, pulmonary function, sputum induction, exhaled nitric oxide measurement and bronchodilator reversibility test, etc.
Efficacy
Confirmatory
Pragmatic
Phase IV
Parameters of impulse oscillometry
1)Indices of chest computed tomography
2)Indices of airway responsiveness
3)Indices of pulmonary function
4)Eosinophil counts in induced sputum
5)Exhaled nitric oxide concentrations
6)Biamarkers of blood
7)Scores of questionnaires
8)Abnormal lung sounds in auscultation
9)Frequency of execerbations
10)Indices of temporal bone and paranasal sinuses computed tomography
11)Biomarkers of middle-ear effusion and pituita
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Inject omalizumab 75-375 mg every 2 or 4 weeks subcutaneously
16 | years-old | <= |
Not applicable |
Male and Female
1)Severe asthma patients who not only meet the Japanese guideline definition of Step4, but are still poorly controlled despite multiple controller medications including high-dose inhaled corticosteroid.
2)Patients whose concentration of serum total IgE is from 30 to 700 IU/ml, and whose body weight is from 30 to 150 kg.
3)Patients who gave consult to the study.
1)Patients with hypersensitiviry to omalizumab
2)Patients with obstructive lung diseases such as chronic bronchitis or COPD, or bronchiectasis
3)Pregnancy or lactation
4)Patients with non-atopic diseases associated with elevated serum total IgE levels
5)Patients who are considered inappropriate by physicians in charge
30
1st name | Hisako |
Middle name | |
Last name | Matsumoto |
Kyoto University Graduate School of Medicine
Department of Respiratory Medicine
606-8507
54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto, Japan
075-751-3830
hmatsumo@kuhp.kyoto-u.ac.jp
1st name | Tomoko |
Middle name | |
Last name | Tajiri |
Kyoto University Graduate School of Medicine
Department of Respiratory Medicine
606-8507
54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto, Japan
075-751-3830
hmatsumo@kuhp.kyoto-u.ac.jp
Kyoto University Graduate School of Medicine
Kyoto University Graduate School of Medicine
Self funding
Japanese Red Cross Wakayama Medical Center
None
Kyoto University Graduate School and Faculty of Medicine, Ethics Committee
54 Kahawara Shogo-in Sakyo-ku Kyoto-shi
075-753-4642
ethcom@kuhp.kyoto-u.ac.jp
NO
京都大学医学部附属病院
2009 | Year | 08 | Month | 26 | Day |
Published
Completed
2009 | Year | 04 | Month | 27 | Day |
2009 | Year | 04 | Month | 27 | Day |
2009 | Year | 08 | Month | 01 | Day |
2014 | Year | 03 | Month | 01 | Day |
2009 | Year | 08 | Month | 26 | Day |
2023 | Year | 02 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002935